Trial Profile
A Phase I Dose Escalation Trial of Donor T Cells Sensitized With Pentadecapeptides of the CMV-PP65 Protein for the Treatment of CMV Infections Following Allogeneic Hematopoietic Stem Cell Transplants
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Adimlecleucel (Primary)
- Indications Cytomegalovirus infections
- Focus Adverse reactions
- Sponsors Atara Biotherapeutics
- 27 Feb 2017 Status changed from active, no longer recruiting to completed.
- 11 Nov 2015 New trial record